XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Commitments and Contingencies (Tables)
 6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contractual Clinical Trials

The following is a summary of the Company’s ongoing contractual clinical trials described below as of June 30, 2024:

 

Schedule of Contractual Clinical Trials 

Description of

Clinical Trial

  Institution  Start Date  Projected End Date 

Number of Patients

in Trial

   Study Objective  Clinical Update 

Expected

Date of Preliminary Efficacy

Signal

  NCT No. 

Remaining

Financial

Contractual

Commitment

 
                              
LB-100 combined with atezolizumab in microsatellite stable metastatic colon cancer (Phase 1b)   Netherlands Cancer Institute (NKI)  September 2024  December 2026   37   Determine RP2D with atezolizumab  Trial planned to open to accrual in 3rd quarter 2024  June 2026  NCT06012734   -(1)
                                
LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b)  GEIS  June 2023  Recruitment completed June 2024   9 to 18   Determine MTD and RP2D  Twelve patients entered  December 2024  NCT05809830  $267,000 
                                
Doxorubicin with or without LB-100 in advanced soft tissue sarcoma (Randomized Phase 2)  GEIS  TBD  TBD   150   Determine efficacy: PFS  Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)  December 2026  NCT05809830  $3,200,000 
                                
LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2)  MD Anderson  January 2024  December 2027   21   Determine the OS of patients with ovarian clear cell carcinoma  Three patients entered  December 2026  NCT06065462   -(1)
                                
Total                            $3,467,000 

 

(1)

The Company has no financial contractual commitment associated with this clinical trial at June 30, 2024.